AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

Published: 2025-06-30 09:03:11 ET ABBV

Published on 06/30/2025 at 09:03

By Denny Jacob

AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash.

The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309, which is currently in Phase 1 and in development for the treatment of B cell-mediated autoimmune diseases.

AbbVie said it will also be acquiring Capstan's proprietary tNLP platform technology.

Write to Denny Jacob at [email protected]

(END) Dow Jones Newswires

06-30-25 0902ET